VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter to underscore the test's potential.
According to VolitionRx, multiple studies have demonstrated that its Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. The company noted that most of the supporting research has been peer reviewed and published, with experts observing consistency across multiple countries and patient populations.
VolitionRx believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. The full press release can be viewed at https://ibn.fm/2IH3m.
Sepsis is a life-threatening condition that affects millions worldwide, and early detection is critical for improving outcomes. The Nu.Q NETs test, which measures nucleosome levels associated with NETosis—a process where neutrophils release web-like structures to trap pathogens—offers a potential tool for rapid diagnosis and monitoring. The growing evidence base could pave the way for broader clinical adoption and impact patient care protocols.
VolitionRx is a multinational company focused on advancing the science of epigenetics. Through its subsidiaries, it develops and commercializes simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. More information is available at https://volition.com/.
